Evaluation of the inhibition of allergen-induced intracutaneous reactions by a new beta-agonist, KWD 2131, and by terbutaline.
In a double-blind crossover study, the wheal inhibiting effect of a new beta-agonist, KWD 2131, and terbutaline was evaluated. The substances were given intracutaneously in five different concentrations, each together with specific allergen or with histamine. During the 2 days' study, 10 patients with known type I-allergy in the skin were randomly assigned to the KWD 2131 or terbutaline group. Both substances gave a dose-dependent inhibition of the allergen-induced wheals. They were, in this respect, equipotent. The greatest protective effect was obtained with the highest doses of both substances (250 micrograms KWD 2131; 25 micrograms terbutaline). In these doses, the inhibition with KWD 2131 and terbutaline was 55 and 45%, respectively (P less than 0.001). Significant inhibition was also seen with the two following lower doses of both substances i.e. 100 and 25 micrograms KWD 2131 and 10 and 2.5 micrograms terbutaline (P less than 0.001-0.01). KWD 2131 and terbutaline did not show any dose-dependent inhibition of histamine-induced wheals. Statistically significant protection against histamine was only reached with the highest dose KWD 2131 (250 micrograms) (P less than 0.05). We conclude that the inhibitory effect of KWD 2131 and of terbutaline on allergen-induced wheal formation in the dose-range tested, is of a selected anti-allergic quality.
D000318:Adrenergic beta-Agonists / Q000627:therapeutic use*; D000328:Adult; D000485:Allergens / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006967:Hypersensitivity / Q000517:prevention & control*; D008297:Male; D013726:Terbutaline / Q000031:analogs & derivatives* / Q000627:therapeutic use*
D000318:Adrenergic beta-Agonists; D000485:Allergens; C025075:KWD 2131; D013726:Terbutaline